COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01945593




Registration number
NCT01945593
Ethics application status
Date submitted
16/09/2013
Date registered
18/09/2013
Date last updated
19/11/2019

Titles & IDs
Public title
BAX 855 Continuation
Scientific title
A Phase 3b Continuation Study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients With Severe Hemophilia A
Secondary ID [1] 0 0
2013-002236-24
Secondary ID [2] 0 0
261302
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hemophilia A 0 0
Condition category
Condition code
Blood 0 0 0 0
Clotting disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - BAX855

Experimental: Fixed BAX855 prophylaxis - 45-80 IU/kg twice weekly to once per week.

Experimental: Pharmacokinetic (PK)-tailored BAX 855 prophylaxis - PK-tailored prophylactic BAX855 regimen based on participant's individual PK profile to maintain a Factor VIII (FVIII) trough level


Other interventions: BAX855
Antihemophilic Factor (Recombinant), PEGylated

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Inhibitory Antibodies to Factor VIII (FVIII) - Inhibitory antibodies to Factor VIII were measured by the Nijmegen modification of the Bethesda assay. Inhibitors had to be confirmed by 2 separate assessments within a 2 to 4 week period from the central laboratory.
Timepoint [1] 0 0
Baseline through end of study (53 months)
Primary outcome [2] 0 0
Annualized Bleed Rate (ABR) - Spontaneous Bleeds - The ABR was assessed based upon each individual bleeding episode. A bleeding episode was defined as subjective (pain consistent with a joint bleed) or objective evidence of bleeding which may or may not require treatment with FVIII. The ABR of spontaneous bleeds was reported separately for twice weekly, PK-t R, each of the every 5 days and every 7 days treatment regimens at the time of bleed.
Timepoint [2] 0 0
Baseline through end of study (53 months)
Secondary outcome [1] 0 0
Total Annualized Bleed Rate (ABR) - The ABR was assessed based upon each individual bleeding episode. A bleeding episode was defined as subjective (pain consistent with a joint bleed) or objective evidence of bleeding which may or may not require treatment with FVIII. Bleeding occurring at multiple locations related to the same injury (e.g., knee and ankle bleed following a fall) was counted as a single bleeding episode. Total annualized bleed rate (spontaneous and traumatic bleeding episodes) was reported.
Timepoint [1] 0 0
Baseline through end of study (53 months)
Secondary outcome [2] 0 0
Overall Hemostatic Efficacy Rating of BAX 855 for Treatment of Breakthrough Bleeding Episodes - The participant or caregiver rated the overall treatment response at 24 (+/- 2) hours after the initiation of treatment using a 4-point efficacy rating scale as Excellent: Full relief of pain and cessation of objective signs of bleeding after a single infusion and no additional infusion is required for the control of bleeding; Good: Definite pain relief and/or improvement in signs of bleeding after a single infusion and possibly requires more than 1 infusion for complete resolution; Fair: Slight relief of pain and slight improvement in signs of bleeding after a single infusion and required more than 1 infusion for complete resolution and None: No improvement or condition worsens.
Timepoint [2] 0 0
Baseline through end of study (53 months)
Secondary outcome [3] 0 0
BAX 855 Infusions Needed to Treat Bleeding Episodes - The BAX 855 infusions to treat each bleeding episode was determined by the participant, the participant's caregiver, and/or investigator, and was based upon the participant's response to treatment. A bleeding episode was defined as subjective (pain consistent with a joint bleed) or objective evidence of bleeding which may or may not require treatment with FVIII.
Timepoint [3] 0 0
Baseline through end of study (53 months)
Secondary outcome [4] 0 0
Total Time Intervals Between Bleeding Episodes - The time interval between bleeding episodes was calculated based upon the date and time reported for each bleeding episode. A bleeding episode was defined as subjective (pain consistent with a joint bleed) or objective evidence of bleeding which may or may not require treatment with FVIII.
Timepoint [4] 0 0
Baseline through end of study (53 months)
Secondary outcome [5] 0 0
Average Dose of BAX 855 Per Prophylactic Infusion - The average dose of BAX 855 per prophylactic infusion was reported.
Timepoint [5] 0 0
Baseline through end of study (53 months)
Secondary outcome [6] 0 0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - An AE was any unfavorable and unintended sign (eg, an abnormal laboratory finding), symptom (eg, rash, pain, discomfort, fever, dizziness, etc.), disease (eg, peritonitis, bacteremia, etc.), or outcome of death temporally associated with the use of an investigational product (IP), whether or not considered causally related to the IP. A serious adverse event (SAE) was defined as an untoward medical occurrence that at any dose met one or more of the following criteria: outcome was fatal/resulted in death; was life-threatening; required inpatient hospitalization or resulted in prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was a medically important event.
Timepoint [6] 0 0
Baseline through end of study (53 months)
Secondary outcome [7] 0 0
Change From Baseline in Body Temperature - Change in body temperature at pre-infusion and post-infusion at end of the study was reported. In the below table, FDR refers to fixed dose regimen, PK-tR refers to PK tailored regimen at the time of sampling.
Timepoint [7] 0 0
Baseline, end of study (53 months)
Secondary outcome [8] 0 0
Change From Baseline in Pulse Rate - Change in pulse rate at pre-infusion and post-infusion at end of the study was reported. In the below table, FDR refers to fixed dose regimen, PK-tR refers to PK tailored regimen at the time of sampling.
Timepoint [8] 0 0
Baseline, end of study (53 months)
Secondary outcome [9] 0 0
Change From Baseline in Respiratory Rate - Change in respiratory rate at pre-infusion and post-infusion at end of the study was reported. In the below table, FDR refers to fixed dose regimen, PK-tR refers to PK tailored regimen at the time of sampling.
Timepoint [9] 0 0
Baseline, end of study (53 months)
Secondary outcome [10] 0 0
Change From Baseline in Blood Pressure - Change in systolic and diastolic blood pressure at pre-infusion and post-infusion at end of the study were reported. In the below table, FDR refers to fixed dose regimen, PK-tR refers to PK tailored regimen at the time of sampling, SBP refers to systolic blood pressure, DBP refers to diastolic blood pressure.
Timepoint [10] 0 0
Baseline, end of study (53 months)
Secondary outcome [11] 0 0
Number of Participants With Shifts in Clinical Chemistry Laboratory Assessments. - The number of participants with clinically significant shifts from "normal" "abnormal clinically significant (CS)" and "abnormal not clinically significant (abnormal NCS)" at baseline to "normal" "abnormal clinically significant (CS) and abnormal clinically significant (NCS)" at completion were reported. In the below table, FDR refers to fixed dose regimen at the time of sampling, AlA refers to alanine aminotransferase, AP refers to alkaline phosphatase, AsA refers to aspartate aminotransferase.
Timepoint [11] 0 0
Baseline through end of study (53 months)
Secondary outcome [12] 0 0
Number of Participants With Shifts in Hematology Laboratory Assessments - The number of participants with clinically significant shifts from "normal" "abnormal clinically significant (CS)" and "abnormal not clinically significant (abnormal NCS)" at baseline to "normal" "abnormal clinically significant (CS) and abnormal clinically significant (NCS)" at completion were reported. In the below table, FDR refers to fixed dose regimen, PK-tR refers to PK tailored regimen at the time of sampling, Leu refers to leukocytes, MCV refers to mean corpuscular volume, Lym/Leu refers to lymphocytes/leukocytes.
Timepoint [12] 0 0
Baseline through end of study (53 months)
Secondary outcome [13] 0 0
Number of Participants With Shifts in Lipid Panel Assessments - The number of participants with clinically significant shifts from "normal" "abnormal clinically significant (CS)" and "abnormal not clinically significant (abnormal NCS)" at baseline to "normal" "abnormal clinically significant (CS) and abnormal clinically significant (NCS)" at completion were reported.. In the below table, HDL refers to high density lipoprotein, LDL refers to low density lipoprotein, VLDL refers to very low density lipoprotein.
Timepoint [13] 0 0
Baseline through end of study (53 months)
Secondary outcome [14] 0 0
Number of Participants With Binding Antibodies - Binding antibodies (IgG and IgM) against FVIII, polyethylene glycol (PEG) and PEGylated FVIII (PEG-FVIII) were analyzed using enzyme-linked immunosorbent assay (ELISA).
Timepoint [14] 0 0
Baseline through end of study (53 months)
Secondary outcome [15] 0 0
Number of Participants With Anti-Chinese Hamster Ovary (CHO) Antibodies - Testing for binding of anti-CHO protein antibodies was performed on citrate-anti-coagulated plasma using an ELISA employing polyclonal antihuman IgG antibodies.
Timepoint [15] 0 0
Baseline through end of study (53 months)
Secondary outcome [16] 0 0
Change From Baseline in Bleed Severity - Hemophilia symptom (haemo-SYM) questionnaire has two subscales: pain and bleed. It was used to asses the bleed severity for participants >=18 years of age as: severity of spontaneous bleeding in my joints (unrelated to injury or activity), spontaneous bleeding in my muscles (unrelated to injury or activity), prolonged bleeding after injury in spite of treatment, intense pain because of bleeding event, joint pain due to active bleed and bleeding during personal hygiene routine, blood in my urine, nose bleeds and assigned a score of 0=Absent, 1=very mild, 2=mild, 3=moderate, 4=severe and 5=very severe. The score was determined as (mean score/5)*100 where mean score is the mean of the available results in the particular subscale. Higher scores on the Haemo-SYM indicate more severe symptoms. Therefore, negative change scores indicate that symptoms have improved. Here 'n' refers to the number of participants evaluable for this endpoint.
Timepoint [16] 0 0
Baseline, end of study (53 months)
Secondary outcome [17] 0 0
Change From Baseline in Pain Severity - Hemophilia symptom (haemo-SYM) questionnaire has two subscales: pain and bleed. It was used to asses the pain severity for participants >=18 years of age as: pain because of swelling in my joints, climbing stairs, upon waking in the morning, active arthritis; constant pain, in my muscles, that needs medication; joint sensitivity to weather conditions; reduced range of joint movement, joint deformity, sleep disturbance because of pain or bleeds, blood in my urine, nose bleeds and assigned a score of 0=Absent, 1=very mild, 2=mild, 3=moderate, 4=severe and 5=very severe. The score was determined as (mean score/5)*100 where mean score is the mean of the available results in the particular subscale. Higher scores on the Haemo-SYM indicate more severe symptoms. Therefore, negative change scores indicate that symptoms have improved. Here 'n' refers to the number of participants evaluable for this endpoint.
Timepoint [17] 0 0
Baseline, end of study (53 months)
Secondary outcome [18] 0 0
Change From Baseline in Patient Reported Outcomes: Health-related Quality of Life (HRQoL): Short Form-36 (SF-36) - HRQoL in participants aged >=14 years was measured using the SF-36 questionnaire. The questionnaire was divided into 8 domains and scored as:
physical functioning (1=yes, limited a lot to 3=no, not limited at all), role-physical (1=all of the time to 5=none of the time), bodily pain (1=very severe to 6=none), general health (1=poor to 5=excellent), vitality (1=none of the time to 5=all of the time), social functioning (1=all of the time: to 5=none of the time), role emotional (1=all of the time to 5=none of the time) and mental health (1=all of the time to 5=none of the time). The score for each domain is then to be transformed to a 0-100 range as [(actual raw score-lowest possible raw score)/possible raw score range]*100. Positive change scores indicate improved HRQoL. in the below table 'FDR' indicates fixed dose regimen, 'PK-tr' indicates pharmacokinetically tailored regimen and 'n' refers to the number of participants evaluable for this endpoint.
Timepoint [18] 0 0
Baseline, end of study (53 months)
Secondary outcome [19] 0 0
Change From Baseline in Patient Reported Outcomes: Health-related Quality of Life (HRQoL): Pediatrics Quality of Life (PedsQL) Questionnaire - HRQoL in participants aged <14 years was measured using the PedsQL. It capture data for the following domains: physical functioning, emotional functioning, social functioning, school functioning, psychosocial functioning, physical health and a total score. Each question of the PedsQL was scored as Never: 100, almost never: 75, sometimes: 50, often: 25, almost always: 0. The mean of the individual question scores was calculated. Lower scores on the PedsQL indicating worse HRQoL. Here, FDR refers to fixed dose regimen, PK-t R refers to PK-tailored regimen. Here 'n' refers to the number of participants evaluable for this endpoint. Here 'n' refers to the number of participants evaluable for this endpoint.
Timepoint [19] 0 0
Baseline, end of study (53 months)

Eligibility
Key inclusion criteria
INCLUSION CRITERIA

Participants Transitioning from Other BAX 855 Studies:

Participants transitioning from other BAX 855 studies can be provided with the continuation
study informed consent form (ICF) prior to the end of study visit to review and consider
participation in this continuation study. These participants will complete any additional
screening assessments within 2 weeks of the previous study's end of study visit and will
return to the study site within 6 (± 1) weeks of the previous study end of study visit to
confirm eligibility for this continuation study.

- Participants transitioning from other BAX 855 studies who meet ALL of the following
criteria are eligible for this study:

1. Participant has completed a previous BAX 855 study and is willing to immediately
transition into this continuation study.

2. Participant is =75 years of age at screening of the previous BAX 855 study.

3. Participant continues to have a Karnofsky (for participants aged = 16 years) or
Lansky (for participants aged < 16 years) performance score of = 60.

4. Participant is human immunodeficiency virus negative (HIV-); or HIV+ with stable
disease and CD4+ count = 200 cells/mm^3, as confirmed by central laboratory at
screening.

5. Participant is hepatitis C virus negative (HCV-) by antibody or polymerase chain
reaction (PCR) testing (if positive, antibody titer will be confirmed by PCR), as
confirmed by central laboratory at screening; or HCV+ with chronic stable
hepatitis.

6. If female of childbearing potential, participant presents with a negative urine
pregnancy test and agrees to employ adequate birth control measures for the
duration of the study.

7. Participant and/or legally authorized representative is willing and able to
comply with the requirements of the protocol.

- BAX 855 Naïve Participants:

BAX 855 naïve participants who are = 12 years of age can only be enrolled in this
continuation study after enrollment in the phase 2/3 pivotal study is closed. BAX 855 naïve
participants who are < 12 years of age can only be enrolled in this continuation study
after enrollment in the pediatric previously treated patient (PTP) study is closed.

- Enrolment of BAX 855 naïve participants will only start once the sponsor has notified the
study sites accordingly.

BAX 855 naïve participants who meet ALL of the following criteria are eligible for this
study:

1. Participant is =75 years of age at screening.

2. Participant is naïve to BAX 855.

3. Participant has severe hemophilia A (FVIII clotting activity < 1%) as confirmed by
central laboratory at screening after at least a 72-hour washout period.

4. Participant aged = 6 years has documented previous treatment with plasma-derived FVIII
or rFVIII for = 150 exposure days (EDs).

5. Participant aged < 6 years has documented previous treatment with plasma-derived FVIII
concentrates or rFVIII for = 50 EDs.

6. Participant is currently receiving prophylaxis or on-demand therapy with FVIII.

7. Participant has a Karnofsky (for participants aged = 16 years) or Lansky (for
participants aged < 16 years) performance score of = 60.

8. Participant is HIV-; or HIV+ with stable disease and CD4+ count = 200 cells/mm^3, as
confirmed by central laboratory at screening.

9. Participant is HCV- by antibody or PCR testing (if positive, antibody titer will be
confirmed by PCR), as confirmed by central laboratory at screening; or HCV+ with
chronic stable hepatitis.

10. If female of childbearing potential, participant presents with a negative urine
pregnancy test and agrees to employ adequate birth control measures for the duration
of the study.

11. Participant and/or legally authorized representative is willing and able to comply
with the requirements of the protocol.

EXCLUSION CRITERA

- Participants Transitioning from Other BAX 855 Studies:

Participants transitioning from other BAX 855 studies who meet ANY of the following
criteria are not eligible for this study:

1. Participant had detectable factor VIII (FVIII) inhibitory antibodies (= 0.6 Bethesda
unit (BU) using the Nijmegen modification of the Bethesda assay) as confirmed by
central laboratory at screening.

2. Participant has developed FVIII inhibitory antibodies (= 0.6 BU using the Nijmegen
modification of the Bethesda assay as determined at central laboratory in a previous
BAX 855 study).

3. Participant has acquired a hemostatic defect other than hemophilia A (eg, qualitative
platelet defect or von Willebrand's disease) in a previous BAX 855 study.

4. Participant has severe chronic hepatic dysfunction (eg, = 5 times upper limit of
normal alanine aminotransferase [ALT], as confirmed by central laboratory at
screening).

5. Participant has severe renal impairment (serum creatinine > 2.0 mg/dL), as confirmed
by central laboratory at screening.

6. Participant experienced a life-threatening or gastrointestinal bleeding episode within
3 months prior to study entry.

7. Participant is scheduled to use other PEGylated drugs during study participation.

8. Participant is planning to take part in any other clinical study during the course of
the continuation study, with the exception of any other parallel BAX 855 study.

9. Participant has medical, psychiatric, or cognitive illness or recreational
drug/alcohol use that, in the opinion of the investigator, would affect participant
safety or compliance.

10. Participant is a family member or employee of the investigator.

- BAX 855 Naïve Participants:

BAX 855 naïve participants who meet ANY of the following criteria are not eligible for this
study:

1. Participant has detectable FVIII inhibitory antibodies (= 0.6 BU using the Nijmegen
modification of the Bethesda assay) as confirmed by central laboratory at screening.

2. Participant has history of FVIII inhibitory antibodies (= 0.6 BU using the Nijmegen
modification of the Bethesda assay or the Bethesda assay) at any time prior to
screening.

3. Participant has been diagnosed with an inherited or acquired hemostatic defect other
than hemophilia A (eg, qualitative platelet defect or von Willebrand's disease).

4. Participant has known hypersensitivity towards mouse or hamster proteins, polyethylene
glycol (PEG), or Tween 80.

5. Participant has severe chronic hepatic dysfunction eg, = 5 times upper limit of normal
ALT, as confirmed by central laboratory at screening).

6. Participant has severe renal impairment (serum creatinine > 2.0 mg/dL), as confirmed
by central laboratory at screening.

7. Participant experienced a life-threatening or gastrointestinal bleeding episode within
3 months prior to study entry.

8. Participant has current or recent (< 30 days) use of other PEGylated drugs prior to
study participation or scheduled use of such drugs during study participation.

9. Participant has participated in another clinical study involving an IP other than BAX
855 or device within 30 days prior to enrollment or is scheduled to participate in
another clinical study involving an investigational product (IP) or investigational
device during the course of this study.

10. Participant has medical, psychiatric, or cognitive illness or recreational
drug/alcohol use that, in the opinion of the investigator, would affect participant
safety or compliance.

11. Participant is a family member or employee of the investigator.
Minimum age
No limit
Maximum age
75 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [3] 0 0
Fremantle Hospital - Fremantle
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Oklahoma
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Utah
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
Austria
State/province [16] 0 0
Linz
Country [17] 0 0
Austria
State/province [17] 0 0
Vienna
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Plovdiv
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Sofia
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Varna
Country [21] 0 0
Czechia
State/province [21] 0 0
Brno
Country [22] 0 0
Czechia
State/province [22] 0 0
Olomouc
Country [23] 0 0
Czechia
State/province [23] 0 0
Praha 5
Country [24] 0 0
Germany
State/province [24] 0 0
Niedersachsen
Country [25] 0 0
Germany
State/province [25] 0 0
Nordrhein Westfalen
Country [26] 0 0
Germany
State/province [26] 0 0
Berlin
Country [27] 0 0
Germany
State/province [27] 0 0
Hamburg
Country [28] 0 0
Hong Kong
State/province [28] 0 0
Shatin
Country [29] 0 0
Israel
State/province [29] 0 0
Haifa
Country [30] 0 0
Israel
State/province [30] 0 0
Ramat-Gan
Country [31] 0 0
Japan
State/province [31] 0 0
Aichi-Ken
Country [32] 0 0
Japan
State/province [32] 0 0
Fukuoka-Ken
Country [33] 0 0
Japan
State/province [33] 0 0
Hiroshima-Ken
Country [34] 0 0
Japan
State/province [34] 0 0
Kanagawa-Ken
Country [35] 0 0
Japan
State/province [35] 0 0
Nara-Ken
Country [36] 0 0
Japan
State/province [36] 0 0
Tokyo-To
Country [37] 0 0
Korea, Republic of
State/province [37] 0 0
Jeollanam-do
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Busan
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Daejeon
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Seoul
Country [41] 0 0
Korea, Republic of
State/province [41] 0 0
Ulsan
Country [42] 0 0
Lithuania
State/province [42] 0 0
Vilnius
Country [43] 0 0
Malaysia
State/province [43] 0 0
Pulau Pinang
Country [44] 0 0
Malaysia
State/province [44] 0 0
Sarawak
Country [45] 0 0
Malaysia
State/province [45] 0 0
Selangor
Country [46] 0 0
Malaysia
State/province [46] 0 0
Kuala Lumpur
Country [47] 0 0
Netherlands
State/province [47] 0 0
Amsterdam
Country [48] 0 0
Poland
State/province [48] 0 0
Gdansk
Country [49] 0 0
Poland
State/province [49] 0 0
Lodz
Country [50] 0 0
Romania
State/province [50] 0 0
Bucuresti
Country [51] 0 0
Russian Federation
State/province [51] 0 0
Kirov
Country [52] 0 0
Russian Federation
State/province [52] 0 0
Krasnoyarsk
Country [53] 0 0
Spain
State/province [53] 0 0
Baleares
Country [54] 0 0
Spain
State/province [54] 0 0
La Coruña
Country [55] 0 0
Spain
State/province [55] 0 0
Málaga
Country [56] 0 0
Spain
State/province [56] 0 0
Madrid
Country [57] 0 0
Spain
State/province [57] 0 0
Valencia
Country [58] 0 0
Sweden
State/province [58] 0 0
Malmo
Country [59] 0 0
Sweden
State/province [59] 0 0
Stockholm
Country [60] 0 0
Switzerland
State/province [60] 0 0
Zuerich
Country [61] 0 0
Taiwan
State/province [61] 0 0
Taichung
Country [62] 0 0
Taiwan
State/province [62] 0 0
Taipei
Country [63] 0 0
Turkey
State/province [63] 0 0
Ankara
Country [64] 0 0
Turkey
State/province [64] 0 0
Antalya
Country [65] 0 0
Turkey
State/province [65] 0 0
Istanbul
Country [66] 0 0
Ukraine
State/province [66] 0 0
Donetsk
Country [67] 0 0
Ukraine
State/province [67] 0 0
Lviv
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Avon
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Greater London
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Greater Manchester
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Hampshire
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Leicestershire
Country [73] 0 0
United Kingdom
State/province [73] 0 0
West Midlands
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Baxalta now part of Shire
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Baxalta Innovations GmbH, now part of Shire
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
To continue the evaluation of the safety and efficacy of BAX 855 for prophylaxis and
treatment of bleeding episodes in adult and pediatric previously treated patients (PTPs) aged
= 75 years of age with severe hemophilia A.
Trial website
https://clinicaltrials.gov/show/NCT01945593
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Shire
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications